Update shared on15 Aug 2025
With both the discount rate and consensus revenue growth forecasts for Heron Therapeutics remaining stable, the consensus analyst price target has consequently held steady at $4.75 per share.
What's in the News
- Reaffirmed Q1 2025 net revenue guidance of $153.0 million to $163.0 million.
- Entered into a note purchase agreement to issue senior unsecured convertible promissory notes for $35 million; notes carry a 5% interest rate, are due in 2031, and are convertible at $1.80 per share.
- Announced a securities purchase agreement to issue 13,225,227 unregistered common shares at $1.50 per share for $19.8 million in gross proceeds, and 5,241,410 unregistered series A convertible preferred stock for $7.9 million, convertible into common shares upon stockholder approval.
- Aggregate gross proceeds from private placements total approximately $62.7 million.
Valuation Changes
Summary of Valuation Changes for Heron Therapeutics
- The Consensus Analyst Price Target remained effectively unchanged, at $4.75.
- The Discount Rate for Heron Therapeutics remained effectively unchanged, at 7.95%.
- The Consensus Revenue Growth forecasts for Heron Therapeutics remained effectively unchanged, at 15.4% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.